Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2020 | The evolving landscape of migraine treatment and prevention

Uwe Reuter, MD, PhD, MBA, Charité – University Medicine Berlin, Berlin, Germany, outlines the evolving landscape of migraine treatment, including lasmiditan, a serotonin (5-HT)1F receptor agonist and small molecule CGRP receptor antagonists such as ubrogepant and rimegepant. For migraine prevention, Prof. Reuter highlights eptinezumab, an anti-CGRP monoclonal antibody. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).